BSE Mid-Cap News and Updates

Name: Latest research reports of Tata Elxsi Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Tata Elxsi Ltd.
Rating: 1
Author: Prabhudas Lilladhar

Keep track of all breaking news on BSE Mid-Cap from all sources in a single place.

Load latest

Indian Renewable Energy Development Agency Ltd.

11 Jul 2025

159.64

0.40%

Zee, IREDA, TataElxsi, LemonTree, AegisLogistics, Nibe lead 15-stock watchlist for today's trade

Business Line

Will poor numbers sink IREDA? Shareholders throw a spanner in Zee's plans

Indian Renewable Energy Development Agency Ltd. has lost -22.60% in the last 6 Months

Tata Elxsi Ltd.

11 Jul 2025

6380.00

3.25%

Tata Elxsi (TELX IN) Q1FY26 Result Update Optimistic...

Sell: Tata Elxsi Ltd.

Prabhudas Lilladhar

Margins declined sharply due to missing operating leverage in Q1 The revenue de-growth was in line with our estimates, largely attributed to M&C and H&L, while Transportation business reported flat QoQ CC vs -9.7% QoQ CC in Q4. The transportation business growth is negatively impacted by Tier-1 suppliers, otherwise the deal ramp ups on the Auto OEMs have improved of late and compensating the weakness against Tier-1. The management sounded optimistic to drive growth within Transportation from Q2, while M&C would recover from Q3 led by large deal ramp up. The timely ramp ups of the...

Tata Elxsi Ltd. has an average target of 5420.20 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

11 Jul 2025

2226.10

0.31%

Innovation validated; blockbuster potential unfolds

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

AbbVie partnership signals a new era for Glenmark Pharma (GNP) GNP’s subsidiary, Ichnos Glenmark Innovation (IGI), has signed an exclusive licensing agreement with AbbVie for its lead investigational asset, ISB-2001.

Glenmark Pharmaceuti.. has an average target of 1601.25 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

11 Jul 2025

2226.10

0.31%

Stock Flash

Buy: Glenmark Pharmaceuticals Ltd.

Deven Choksey

Ichnos Glenmark Innovation (IGI), a wholly-owned subsidiary of Glenmark
Pharmaceuticals, has entered into an exclusive global licensing agreement
with AbbVie for the development and commercialization of IGI’s lead
oncology asset, ISB 2001. This first-in-class CD38×BCMA×CD3 trispecific
antibody is currently in Phase 1 clinical trials for relapsed/refractory multiple
myeloma (R/R MM).

Glenmark Pharmaceuti.. has an average target of 1601.25 from 5 brokers.

Tata Elxsi Ltd.

11 Jul 2025

6380.00

3.25%

Weak print; deal ramp-ups from Q2FY26

Sell: Tata Elxsi Ltd.

Target

ICICI Securities Limited

TATA Elxsi (TELX) reported a disappointing print vs I-Sec’s already muted estimates. Q1FY26 marks the fourth straight quarter of muted revenue performance.

Tata Elxsi Ltd. has gained 34.26% in the last 3 Months

JSW Infrastructure Ltd.

10 Jul 2025

310.00

-2.15%

CoC approves JSW Infra's resolution plan for NCR Rail Infrastructure

Business Standard

The Committee of Creditors (CoC) has approved JSW Infra's resolution plan for NCR Rail Infrastructure. The plan, subject to necessary regulatory approvals, aims to expand JSW Infra's logistics

Number of FII/FPI investors increased from 182 to 199 in Mar 2025 qtr.

Tata Elxsi Ltd.

10 Jul 2025

6380.00

3.25%

Tata Elxsi Results Earnings Call for Q1FY26

Conference Call with Tata Elxsi Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.

audio

Crisil Ltd.

10 Jul 2025

5978.50

-0.24%

Private sector debt recast firms' AUM may further shrink, says CRISIL

Business Standard

CRISIL forecasts a 4-6% drop in AUM for private asset reconstruction companies (ARCs) in FY26 due to subdued acquisitions of stressed loans and potential disruptions from loan securitisation